samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > biotechnology and patents from the finnish point of view
PUBLICATIONS
European Biopharmaceutical Review

Biotechnology and Patents From the Finnish Point of View

During the 80s and 90s, there was a remarkable investment boom in Finland in the biotechnological sector, and this trend is still continuing. With more than 115 biotechnology companies, Finland can be ranked amongst the top European countries in terms of number of biotechnological firms.Biotechnology comprises a large sector. Approximately half the businesses operating in Finland concentrate on health products such as pharmaceuticals. In general terms, the use of biotechnology in the pharmaceutical industry is increasing. It is estimated that biotechnology has been used in every fifth new pharmaceutical brought onto the market.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

X-Chem Acquires ComInnex

WALTHAM, Mass.; Oct. 25, 2021 (Business Wire) X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement